Altimmune, Inc. (ALT) News

Altimmune, Inc. (ALT): $9.95

0.49 (+5.18%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ALT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 380

in industry

Filter ALT News Items

ALT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ALT News Highlights

  • ALT's 30 day story count now stands at 7.
  • Over the past 19 days, the trend for ALT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about ALT are MD, NOV and AVDL.

Latest ALT News From Around the Web

Below are the latest news stories about ALTIMMUNE INC that investors may wish to consider to help them evaluate ALT as an investment opportunity.

Altimmune to Participate at Two Upcoming Investor Conferences

GAITHERSBURG, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences: Evercore ISI 5th Annual HealthCONx Virtual ConferenceTuesday, November 29, 2022Fireside chat at 10:55 am Eastern Time Piper Sandler 34th Annual Healthcare Conference in New York, NYThursday, December 1, 2022Fireside chat at 10:00 am Eastern Time The sess

Yahoo | November 22, 2022

Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), 89bio (ETNB) and Avadel Pharmaceuticals (AVDL)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Altimmune (ALT – Research Report), 89bio (ETNB – Research Report) and Avadel Pharmaceuticals (AVDL – Research Report) with bullish sentiments. Altimmune (ALT) In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Altimmune, with a price target of $50.00. The company's shares closed last Friday at $8.84. According to TipRanks.

Christine Brown on TipRanks | November 21, 2022

Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business Update

Topline 24-week data from Phase 1b trial in subjects with non-alcoholic fatty liver disease (NAFLD) expected mid-December 2022 Interim 24-week readout from MOMENTUM Phase 2 obesity trial expected Q1 2023 GAITHERSBURG, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and nine months ended September 30, 2022, and provided a business update. “We continue on course in our advancement of p

Yahoo | November 10, 2022

B.Riley Financial Reaffirms Their Buy Rating on Altimmune (ALT)

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Altimmune (ALT - Research Report), with a price target of $26.00. The company's shares closed yesterday at $11.65.Mamtani covers the Healthcare sector, focusing on stocks such as Altimmune, Novavax, and Intercept Pharma. According to TipRanks, Mamtani has an average return of -30.7% and a 20.11% success rate on recommended stocks. Currently, the analyst consensus on Altimmune is a Strong Buy with an average price target of $31.67, a 171.85% upside from current levels. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $28.00 price target.

Christine Brown on TipRanks | November 8, 2022

B.Riley Financial Sticks to Its Buy Rating for Altimmune (ALT)

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Altimmune (ALT - Research Report), with a price target of $26.00. The company's shares opened today at $12.21.Mamtani covers the Healthcare sector, focusing on stocks such as Altimmune, Novavax, and Intercept Pharma. According to TipRanks, Mamtani has an average return of -30.4% and a 21.02% success rate on recommended stocks. Currently, the analyst consensus on Altimmune is a Strong Buy with an average price target of $31.67.

Christine Brown on TipRanks | November 4, 2022

Altimmune to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10

GAITHERSBURG, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2022 financial results on Thursday, November 10, 2022 and will provide a business update.

GlobeNewswire | November 3, 2022

Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting

GAITHERSBURG, Md., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company will be presenting at two upcoming scientific conferences in November 2022: American Heart Association Scientific Sessions 2022, Chicago, ILSaturday, November 5, 2022 Poster Presentation at 11:00 am Central TimeTitle: Effect

Wallstreet:Online | October 28, 2022

Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting®

GAITHERSBURG, Md., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company will be presenting at two upcoming scientific conferences in November 2022: American Heart Association Scientific Sessions 2022, Chicago, ILSaturday, November 5, 2022Poster Presentation at 11:00 am Central TimeTitle: Effect of Pemvidutide (ALT-801), a Novel GLP-1/Glucagon Dual Receptor Agonist, on Pathogenic Lipid MediatorsLead Author: J

Yahoo | October 28, 2022

B.Riley Financial Remains a Buy on Altimmune (ALT)

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Altimmune (ALT - Research Report) today and set a price target of $26.00. The company's shares closed yesterday at $9.98.Mamtani covers the Healthcare sector, focusing on stocks such as Altimmune, Intercept Pharma, and Novavax. According to TipRanks, Mamtani has an average return of -31.3% and a 18.91% success rate on recommended stocks. Currently, the analyst consensus on Altimmune is a Strong Buy with an average price target of $31.67, which is a 217.33% upside from current levels. In a report released on October 6, JMP Securities also reiterated a Buy rating on the stock with a $28.00 price target.

Brian Anderson on TipRanks | October 11, 2022

Weak Fundamental Momentum Pushes Altimmune Inc. (ALT) Lower

Altimmune Inc. (NASDAQ:ALT) has a beta value of 0.43 and has seen 1.44 million shares traded in the last trading session. The company, currently valued at $553.02M, closed the last trade at $10.46 per share which meant it lost -$0.82 on the day or -7.27% during that session. The ALT stock price is -124.57% off … Weak Fundamental Momentum Pushes Altimmune Inc. (ALT) Lower Read More »

Marketing Sentinel | October 10, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6174 seconds.